Announcements

Eligibility Criteria for Amyloid PET and Tau PET in Alzheimer’s Disease

The guidelines originally prepared in 2013 for Amyloid PET imaging alone have been updated in 2024 to include considerations for current anti-amyloid therapies and new clinical research findings. This updated guideline evaluates the appropriateness of performing Amyloid PET and Tau PET for different clinical scenarios separately. You can access the updated guideline here.

New (2024) Diagnostic and Staging Criteria for Alzheimer’s Disease Published

On June 28, 2024, revised criteria for the diagnosis and staging of Alzheimer’s disease (AD) were published by the Alzheimer's Association (AA).

CMS Removed Restrictions on Amyloid PET in the U.S.

In October 2023, the U.S. Centers for Medicare & Medicaid Services (CMS) removed the previous restriction on Amyloid PET imaging. The decision, which was initially imposed in September 2013, now allows Medicare administrative contractors to determine reimbursement for Amyloid PET in dementia patients.

FDA Approved Three Different Anti-Amyloid Treatments for Alzheimer’s Disease

In January 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval for the antibody treatment Lecanemab for Alzheimer’s disease. This treatment aims to clear pathological amyloid deposits in the brain, similar to the previously approved Aducanumab. On July 2, 2024, the FDA also approved the antibody Donanemab for the treatment of mild cognitive impairment or early-stage dementia in Alzheimer’s disease.

2024 Alzheimer’s Disease Facts and Figures Brochure

The Alzheimer’s Association (AA) has published the "2024 Alzheimer’s Disease Facts and Figures" brochure. For this detailed brochure in English, click here.